Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acne Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments

NCT02755545
View directory record Official record
Conditions
Acne
Interventions
Product A, Product B
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
21 Years to 45 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

NCT02959970
View directory record Official record
Conditions
Acne Vulgaris
Interventions
dapsone gel
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Fremont, California • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional

Optical Clearing of the Skin in Conjunction With Laser Treatments

NCT00580736
View directory record Official record
Conditions
Port Wine Stain, Nevus of Ota, Tattoos, Scars, Acne, Hypertrichosis, Sebaceous Gland Diseases
Interventions
Optical Clearing
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Jul 22, 2026, 4:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Photopneumatic System for the Treatment of Acne

NCT01257555
View directory record Official record
Conditions
Mild to Moderate Acne
Interventions
Photopneumatic therapy
Device
Lead sponsor
Solta Medical
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2012 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
55
States / cities
Anaheim, California • Encinitas, California • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 22, 2026, 4:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Restylane Silk Acne Scar Efficacy Evaluation Study

NCT02955381
View directory record Official record
Conditions
Acne, Acne Scars, AdverseEvent
Interventions
Restylane Silk, 1.0 ml, Saline, 1.0 ml
Device
Lead sponsor
Schweiger Dermatology, PLLC
Industry
Eligibility
22 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

NCT02242760
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 2%, SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

NCT03573518
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BTX 1503, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
Little Rock, Arkansas • Encino, California • Murrieta, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of PRK 124 Lotion in Acne Rosacea

NCT00580723
View directory record Official record
Conditions
Acne Rosacea
Interventions
PRK 124
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

NCT01885910
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 100mg, Aczone 5% gel
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars

NCT02643628
View directory record Official record
Conditions
Atrophic Acne Scars
Interventions
Microneedling, Microneedling followed by Bellafill treatment
Procedure · Device
Lead sponsor
Suneva Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jul 22, 2026, 4:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris

NCT01929057
View directory record Official record
Conditions
Acne
Interventions
Skin biopsy, Blood draw
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Jul 22, 2026, 4:20 AM EDT
Active, not recruiting Phase 2 Interventional

Anifrolumab for Hidradenitis Suppurativa

NCT06374212
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

NCT01182636
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, Differin®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

NCT02218034
View directory record Official record
Conditions
Acne Vulgaris
Interventions
AGN-190168 Formulation 1, AGN-190168 Formulation 2, tazarotene gel 0.1%, tazarotene cream 0.1%
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

NCT02066545
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CLS001 Topical Gel, CLS001 Topical Gel Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
12 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
20
States / cities
Encino, California • San Diego, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Jul 22, 2026, 4:20 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the Use of Botox on Acne

NCT00765375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Botulinum Neurotoxin Type A, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects

NCT00446043
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Not applicable Interventional

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

NCT02905851
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Feedback group, Non Feedback group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
15 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 22, 2026, 4:20 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Jul 22, 2026, 4:20 AM EDT